Compare Amphastar Pharmaceuticals Inc (AMPH) vs VanEck Gold Miners ETF (GDX) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

GDX trades at $75.53, down 0.32% with a bearish technical signal from moving averages. The ETF faces near-term pressure from gold price volatility but maintains strong fundamentals with record-high free cash flow yields and attractive valuations at five-year lows according to Seeking Alpha analysis from June 25, 2026. Recent portfolio addition of Aya Gold & Silver enhances diversification.

Long-term outlook remains positive given gold's role as a portfolio diversifier and central bank demand. Key risks include gold price sensitivity and mining cost pressures. Analyst sentiment is mixed with some seeing current levels as a buying opportunity while technical indicators suggest caution in the near term.